Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone‐sensitive prostate cancer-Reference-Cited by-同舟云学术

Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone‐sensitive prostate cancer

Published:2022-11-24 Issue:4 Volume:83 Page:307-315
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Naito Yushi¹^ORCID,Kato Masashi¹^ORCID,Kawanishi Hideji²,Yamamoto Akiyuki³,Sakamoto Fumitoshi⁴,Hirabayashi Hiroki⁵,Kobayashi Masataka⁶,Matsukawa Yoshihisa¹^ORCID,Kimura Tohru⁷,Araki Hidemori⁸,Nishikimi Toshinori⁹,Kondo Atsuya¹⁰,Yoshino Yasushi¹¹,Hashimoto Yoshimasa¹²,Nakano Yojiro¹³,Tsuzuki Toyonori¹⁴^ORCID

Affiliation:

1. Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan

2. Department of Urology Aichi Medical University Hospital Nagakute Japan

3. Department of Urology Toyohashi Municipal Hospital Toyohashi Japan

4. Department of Urology Chubu Rosai Hospital Nagoya Japan

5. Department of Urology Japanese Red Cross Nagoya Daiichi Hospital Nagoya Japan

6. Department of Urology Narita Memorial Hospital Toyohashi Japan

7. Department of Urology Japan Community Healthcare Organization Chukyo Hospital Nagoya Japan

8. Department of Urology Meitetsu Hospital Nagoya Japan

9. Department of Urology Japanese Red Cross Nagoya Daini Hospital Nagoya Japan

10. Department of Urology Kariya Toyota General Hospital Kariya Japan

11. Department of Urology National Hospital Organization Nagoya Medical Center Nagoya Japan

12. Department of Urology Yokkaichi Municipal Hospital Yokkaichi Japan

13. Department of Urology Tosei General Hospital Seto Japan

14. Department of Surgical Pathology Aichi Medical University Hospital Nagakute Japan

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24462

Reference33 articles.

1. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

2. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

3. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

4. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

5. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management;Urologic Oncology: Seminars and Original Investigations;2024-05

2. Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate;International Journal of Urology;2023-09-20

3. Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer;Acta Oncologica;2023-09-15

4. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics;Frontiers in Oncology;2023-08-17

5. Round up;Indian Journal of Urology;2023